Statistics from Altmetric.com
Dr A Patel, University of Sydney, Sydney, New South Wales, Australia; firstname.lastname@example.org
randomised controlled trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE]).
blinded (outcome adjudication committee).*
215 centres in 20 countries in Asia, Australasia, Europe, and North America.
11 140 patients ⩾55 years of age (mean age 66 y, 58% men) who had type 2 diabetes and a history of, or risk factors for, vascular disease. Patients requiring insulin were excluded.
intensive glucose control with gliclazide modified-release, 30–120 mg/d, and other non-sulfonylurea drugs as needed to achieve a target glycated haemoglobin concentration ⩽6.5% (n = 5571) or standard glucose control with drugs other than gliclazide (n = 5569).
composite of macrovascular events (non-fatal myocardial infarction or stroke, or death from cardiovascular causes) and composite of microvascular events (new or worsening nephropathy [including macroalbuminuria] or retinopathy). Secondary outcomes included new-onset microalbuminuria and severe hypoglycaemia.
median 5 years. …
Source of funding: Servier and National Health and Medical Research Council of Australia.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.